Trial · NCT01722331
Participant flow63
How many started, completed or left each group, period by period.
1 to 20 of 63
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part 1 | STARTED | Tildrakizumab 200 mg (Parts 1, 2 & 3) | 308 | |
| Part 1 | STARTED | Tildrakizumab 100 mg (Parts 1, 2 & 3) | 249 | |
| Part 1 | STARTED | Tildrakizumab 100 mg (Parts 1 & 2) | 41 | |
| Part 1 | STARTED | Tildrakizumab 100 mg (Parts 1 & 2)/ 200 mg (Part 3) | 19 | |
| Part 1 | STARTED | Placebo (Part 1) | 9 | |
| Part 1 | STARTED | Placebo (Part 1)/ Tildrakizumab 200 mg (Parts 2 & 3) | 72 | |
| Part 1 | STARTED | Placebo (Part 1)/ Tildrakizumab 100 mg (Parts 2 & 3) | 74 | |
| Part 1 | COMPLETED | Tildrakizumab 200 mg (Parts 1, 2 & 3) | 298 | |
| Part 1 | COMPLETED | Tildrakizumab 100 mg (Parts 1, 2 & 3) | 249 | |
| Part 1 | COMPLETED | Tildrakizumab 100 mg (Parts 1 & 2) | 32 | |
| Part 1 | COMPLETED | Tildrakizumab 100 mg (Parts 1 & 2)/ 200 mg (Part 3) | 19 | |
| Part 1 | COMPLETED | Placebo (Part 1) | 0 | |
| Part 1 | COMPLETED | Placebo (Part 1)/ Tildrakizumab 200 mg (Parts 2 & 3) | 72 | |
| Part 1 | COMPLETED | Placebo (Part 1)/ Tildrakizumab 100 mg (Parts 2 & 3) | 74 | |
| Part 1 | NOT COMPLETED | Tildrakizumab 200 mg (Parts 1, 2 & 3) | 10 | |
| Part 1 | NOT COMPLETED | Tildrakizumab 100 mg (Parts 1, 2 & 3) | 0 | |
| Part 1 | NOT COMPLETED | Tildrakizumab 100 mg (Parts 1 & 2) | 9 | |
| Part 1 | NOT COMPLETED | Tildrakizumab 100 mg (Parts 1 & 2)/ 200 mg (Part 3) | 0 | |
| Part 1 | NOT COMPLETED | Placebo (Part 1) | 9 | |
| Part 1 | NOT COMPLETED | Placebo (Part 1)/ Tildrakizumab 200 mg (Parts 2 & 3) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01722331/flow